Continued European Marketing Authorization for Privigen and its Regulatory Significance

The European Medicines Agency (EMA) has decided to maintain the marketing authorization for Privigen, CSL Behring's leading human normal immunoglobulin (IVIG) product. This decision reaffirms the clinical safety and efficacy that Privigen has demonstrated in the European market for over 18 years since its initial approval in 2008. Passing through rigorous re-evaluation by regulatory authorities is highly significant as it continuously provides confidence in the product for patients with immunodeficiency disorders who require long-term treatment. In particular, by reflecting the latest safety guidelines through numerous revisions, regulatory risks have been minimized, and a stable prescription environment has been maintained.

Clinical Role of Immunoglobulin and Expansion of Indications

The main ingredient of Privigen, Human Normal Immunoglobulin, is essential for the treatment of patients with primary immunodeficiency (PID) and secondary immunodeficiency (SID) who require IgG supplementation. It is also widely used as an immunomodulatory therapy for autoimmune diseases such as Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), in which the immune system attacks normal tissues. Recently, it has been contributing to addressing unmet needs by diversifying its indications, such as for prophylactic use before and after exposure to measles. In clinical practice, this expansion of indications is evaluated as an opportunity to broaden treatment options and directly improve the quality of life for patients.

Competitive Landscape and Analysis of CSL's Market Dominance

The global immunoglobulin market is currently dominated by a few global pharmaceutical companies, including CSL Behring, Takeda, Grifols, and Octapharma. Among these, CSL's Privigen competes fiercely with other leading products such as Takeda's Gammagard and Grifols' Gamunex-C, based on its excellent liquid formulation convenience and accumulated clinical data. By maintaining the stable regulatory status of its flagship product, Privigen, CSL has been able to fend off the pursuit of its competitors and further solidify its leading position. In particular, CSL's supply chain strength, with its large plasma collection infrastructure, is creating a synergistic effect in combination with the maintenance of regulatory approval.

Market Size and Commercial Value of Immunoglobulin

The global immunoglobulin market is estimated at approximately $18.9 billion (USD) in 2024 and is growing at a rapid pace of over 7% per year. CSL Behring's immunoglobulin business recorded sales of $5.66 billion (USD) in fiscal year 2024, a remarkable 20% increase from the previous year. Privigen is a key pipeline product that drives this overall sales growth for CSL and plays a significant role as a cash cow, accounting for the largest share of sales. This EMA's decision to maintain the marketing authorization is expected to completely eliminate uncertainties regarding CSL's medium- to long-term sales trends and provide investors with a strong growth momentum.